As mentioned in the Introduction, “total TF” was recently implicated in the development of resistance to KRAS-G12C inhibitors [10]; as such, asTF-targeting via hRabMab1 may hold future promise in tackling this phenomenon in PDAC and other cancers driven by mutant KRAS. This evidence concerns the gene TF and cancer.